Snapshot of Actavis-Allergan deal

Snapshot of the deal :

Acquired By: Actavis
Acquired Company : Allergan
Deal Value: Approx. 66 Bn
Deal Announcement : Nov 17, 2014
Global Impact of the deal :

The combination will create one of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015. The combined Company will be a leader in a new industry model – Growth Pharma – anchored by world-renowned brand franchises, a leading global generics business, a premier pharmaceutical development pipeline and an experienced management team committed to maintaining highly efficient operations across the organization.

What happen to the Allergan brand name?
Actavis plc (NYSE: ACT) today announced that it will adopt a new corporate name – Allergan – following the anticipated successful completion of the acquisition of Allergan, Inc. The Company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The change in corporate name would be subject to approval by Actavis’ shareholders at its Annual General Meeting later this year.

Actavis plc (NYSE: ACT) today announced that it will adopt a new corporate name – Allergan – following the anticipated successful completion of the acquisition of Allergan, Inc. The Company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The change in corporate name would be subject to approval by Actavis’ shareholders at its Annual General Meeting later this year.

About Allergan

Allergan is a $23 billion diversified global pharmaceutical company and a leader in a new industry model – Growth Pharma. The company is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team creating an unrivaled foundation for long-term growth.

Brand Portfolio
The Allergan Brand portfolio features six blockbuster franchises in key therapeutic categories, including

Dermatology and Aesthetics
CNS
Eye Care
Women’s Health and Urology
GI and Cystic Fibrosis
Cardiovascular and Infectious Disease

Research and Development
Together, our Company is focused on developing new medicines that address unmet medical needs in critical therapeutic areas, as well as increasing global access to high-quality, affordable medicines.

Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015, focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.

Generics Portfolio
The Company’s Generics portfolio features more than 1,000 generics, branded generics, established brands and OTC products. The Company is the third largest generic manufacturer in the U.S. and holds a top 5 leadership position in nearly 20 International markets.

Headquarters
Allergan has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.

About Actavis

Actavis Plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.  The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.